SCHEDULE 13D: Dr. Jordan Balencic Discloses 6.41% Beneficial Ownership in Mitesco, Inc. Through Common and Preferred Stock Holdings

Dr. Jordan Balencic, a director of Mitesco, Inc., has disclosed a 6.41% beneficial ownership stake in the company, primarily acquired through compensation for director and non-director services.

Summary

• Dr. Jordan Balencic, a director of MITESCO, INC., has filed a Schedule 13D disclosing beneficial ownership of 1,220,644 votes, representing 6.41% of the Issuer's total voting power.
• This ownership consists of 260,644 shares of Common Stock and 2,400 shares of Series X Preferred Stock.
• Each Series X Preferred Stock share entitles the holder to 400 votes, contributing 960,000 votes to Dr. Balencic's total.
• The shares were primarily acquired as compensation for director services (2,400 Series X Preferred Stock on January 1, 2024), non-director services (100,000 Common Stock on July 29, 2024, and 150,000 Common Stock on November 12, 2024), and accrued dividends on Series X Preferred Stock (7,190 Common Stock between January 1, 2024, and January 15, 2025, and 3,454 restricted common stock year-to-date 2025).
• The percentage of ownership is calculated based on 19,038,212 total shares of capital stock outstanding as of March 31, 2025, which includes 11,157,012 shares of Common Stock and 19,703 shares of Series X Preferred Stock.
• Dr. Balencic's holdings are stated to be solely for investment purposes, with no current plans for extraordinary corporate transactions or changes to the Issuer's structure or management.

Sentiment

Score: 6

Explanation: The filing is a standard disclosure of a significant beneficial ownership stake by a company director. While not a performance report, the director's accumulation of shares, primarily through compensation, indicates continued alignment of interests with the company. The stated purpose is solely for investment, without immediate plans for corporate changes.

Positives

• A director increasing their stake, even through compensation, can signal confidence in the company's future.
• The filing clarifies the voting power structure, including the significant impact of Series X Preferred Stock.

Negatives

• The acquisition of shares primarily through compensation rather than open market purchases might not reflect direct cash investment by the director.

Risks

• The document does not explicitly state specific risks for the company or the investment, beyond the general statement that the Reporting Person may dispose of shares.

Future Outlook

The Reporting Person intends to evaluate on an ongoing basis the investments in the Issuer and their options with respect to such investments. The Reporting Person may, from time to time, acquire additional shares or dispose of some or all of the beneficially owned shares, if market conditions are favorable. No current plans exist for extraordinary corporate transactions, changes in management, capitalization, or corporate structure.

Industry Context

This filing is a standard disclosure of a significant ownership stake by an insider (a director) in a publicly traded company. It does not provide broader industry trends or competitive analysis, focusing solely on the individual's investment position.

Related Party Transactions

• Issuance of 2,400 shares of Series X Preferred Stock to Dr. Jordan Balencic on January 1, 2024, as compensation for director services.
• Issuance of 7,190 shares of Common Stock to Dr. Jordan Balencic between January 1, 2024, and January 15, 2025, for accrued dividends on Series X Preferred Stock.
• Issuance of 100,000 shares of Common Stock to Dr. Jordan Balencic on July 29, 2024, as compensation for non-director services.
• Issuance of 150,000 shares of Common Stock to Dr. Jordan Balencic on November 12, 2024, as compensation for non-director services.
• Issuance of 3,454 shares of restricted common stock to Dr. Jordan Balencic year-to-date 2025 for dividend payments on Series X Preferred shares.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant insider holding and voting power. The director's investment purpose may align with long-term shareholder value.
• Management: The director's significant stake could potentially influence strategic decisions, although the filing states no current plans for changes.

Next Steps

• Dr. Jordan Balencic may acquire additional shares of Common Stock for investment purposes if market conditions are favorable.
• Dr. Jordan Balencic may dispose of some or all of the beneficially owned shares periodically.

Key Dates

Recommendation

Keywords

MITESCO INC, Jordan Balencic, Schedule 13D, beneficial ownership, common stock, preferred stock, Series X Preferred Stock, director compensation, investment purposes, SEC filing, voting power